产品说明
应用
Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property. It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines
包装
10, 50 mg in glass bottle
生化/生理作用
Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.
基本信息
| 经验(实验)分子式 | C14H12N6O |
| 分子量 | 280.28 |
| MDL编号 | MFCD00867135 |
| PubChem化学物质编号 | 329817628 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 旋光性 | [α]/D -500 to -650°, c = 0.5 in THF |
| 颜色 | yellow |
| 溶解性 | DMSO: ≥20 mg/mL |
| 储存温度 | room temp |
| SMILES string | C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2 |
| InChI | 1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1 |
| InChI key | WHXMKTBCFHIYNQ-SECBINFHSA-N |
| Gene Information | human ... PDE3A(5139), PDE3B(5140), TNNC1(7134), TNNI3(7137), TNNT2(7139) |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 - H312 - H332 |
| 预防措施声明 | P280 |
| 危险分类 | Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
